A newstudyby investigators at Mass General Brigham has found that abloodtestof plasma phosphorylated tau 217 (pTau217), an Alzheimer's disease biomarker, can predict the progression of amyloid PET scan changes and cognitive decline in cognitively healthy older adults. The findings may help push back the clock to enable simpler, earlier disease prediction and indicate who may be at risk ...
Abloodtestapproved by the Food and Drug Administration in May provides an inexpensive and noninvasive way todetectbiomarkers of Alzheimer's disease, vastly increasing opportunities forearlydetection and treatment. Thistestwas developed based on research completed at Johns Hopkins, Lund University and private companies.
Such details provide a deeper understanding and appreciation for Study Blood Test Could Detect Dementia Early.
A newstudyfinds abloodtestanalyzing gut health may predictdementiayears in advance. Learn how gut health and diet can impact brain health.
A newstudyshowed that abloodtestcan estimate when someone will begin to show Alzheimer's symptoms. This could help researchers better design approaches to prevent or treat symptoms.
Summary: For years, the gold standard for spottingearlyAlzheimer's was the amyloid PET scan, which coulddetectbrain plaques 10 to 20 years before symptoms appeared. However, a groundbreakingstudyhas identified a "pre-early" warning sign. Researchers found that abloodtestfor pTau217 ...
The currently availabletestsmay predict the presence of amyloid changes in the brain or the presence of neurodegenerative disease or neuronal damage. Thesebloodtestscannot be used as a stand-alonetestto diagnose Alzheimer's disease or any otherdementia; they will be used as part of a diagnostic workup with other exams.
